Paper Details

  1. Home
  2. Paper Details

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

Author: BagustAdrian, BealeSophie, BolandAngela, DuarteRui, DundarYenal, FleemanNigel, GreenhalghJanette, HounsomeJuliet, HoutenRachel, RichardsonMarty, ShenoyAditya

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Thyroid cancer is a rare cancer, and differentiated thyroid cancer (DTC) is the most common type. Radioactive iodine is often used to treat DTC. For people who don't respond to radioactive iodine, treatment options are limited, and supportive care is often the only approach.
Paper Details　
Original Abstract of the Article :
Thyroid cancer is a rare cancer, accounting for only 1% of all malignancies in England and Wales. Differentiated thyroid cancer (DTC) accounts for ≈94% of all thyroid cancers. Patients with DTC often require treatment with radioactive iodine. Treatment for DTC that is refractory to radioactive iodin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6983913/

データ提供：米国国立医学図書館（NLM）

Lenvatinib and Sorafenib for Differentiated Thyroid Cancer: A Systematic Review and Economic Evaluation

Thyroid cancer is a relatively uncommon cancer, but it can be challenging to treat, especially when it becomes resistant to radioactive iodine. This research focuses on differentiated thyroid cancer (DTC) that is refractory to radioactive iodine (RR-DTC). The study conducted a systematic review and economic evaluation of lenvatinib and sorafenib, two targeted therapies for RR-DTC. The authors analyzed the available evidence to assess the effectiveness and cost-effectiveness of these drugs, providing insights for clinical decision-making.

Navigating the Desert of Treatment Options for Differentiated Thyroid Cancer

Imagine a traveler lost in the desert, searching for a reliable path. For patients with RR-DTC, the journey can be fraught with uncertainty, as traditional treatments may not be effective. This study is like a map, guiding us through the complex landscape of treatment options, providing a systematic review and economic evaluation of lenvatinib and sorafenib.

Making Informed Treatment Decisions: A Balancing Act

Choosing the right treatment for RR-DTC requires a careful balance of factors, including effectiveness, safety, and cost. This study is like a camel navigating a treacherous desert, carefully weighing each option before making a decision. The research provides valuable insights into the cost-effectiveness of lenvatinib and sorafenib, helping healthcare professionals make informed decisions about treatment for RR-DTC patients.

Dr.Camel's Conclusion

This research provides a valuable resource for healthcare professionals and patients dealing with RR-DTC. It's like a desert oasis, offering knowledge and guidance on treatment options and their associated costs. This study highlights the importance of ongoing research and development in the field of thyroid cancer treatment, striving to provide patients with better and more cost-effective therapies.

Date :
  1. Date Completed 2020-10-13
  2. Date Revised 2020-10-13
Further Info :

Pubmed ID

31931920

DOI: Digital Object Identifier

PMC6983913

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.